Corcept Therapeutics Inc expected to post earnings of 43 cents a share - Earnings Preview

Corcept Therapeutics Incorporated

24/02/2025 21:51

* Corcept Therapeutics Inc  CORT.OQ   CORT.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
26 for the period ending December 31 2024
    * The Redwood City California-based  company is expected to
report
a 46.7% increase in revenue to $198.686 million from $135.41
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Corcept Therapeutics Inc
is
for earnings of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Corcept
Therapeutics Inc is $95.50​, above​ its last closing price
of $63.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  0.29        0.28       0.41      Beat    45.4
 Jun. 30 2024  0.24        0.23       0.32      Beat    39.1
 Mar. 31 2024  0.23        0.22       0.25      Beat    13.6​
 Dec. 31 2023  0.27        0.26       0.28      Beat    8.5
 ​​Sep.        0.23        0.22       0.28      Beat    28.2
 30 2023                                                
 Jun. 30 2023  0.15        0.15       0.25      Beat    66.7​
 Mar. 31 2023  0.19        0.19       0.14      Missed  -27.6
 Dec. 31 2022  0.23        0.23       0.14      Missed  -37.8
 This summary was machine generated February 24 at 21:51 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)